Why is Erasca stock sliding today?
Erasca (ERAS) stock fell 4.9% to $14.375 after HC Wainwright widened its FY2027-FY2030 loss forecasts. Leerink initiated coverage with an Outperform rating and $35 target, but the positive outlook was overshadowed by the downgrade and insider selling. The broader market decline also contributed to the sell-off.
How this was made
The 30-second read
Why it matters
The immediate catalyst is HC Wainwright materially lowering loss estimates across FY2027-FY2030, which the article links to today’s ~4.9% decline. A Form 144 filing tied to an insider share sale adds caution, while Leerink’s bullish initiation is not enough to offset the negative revisions.
Market read
For ERAS traders, the key decision is whether to fade the dip or wait for stabilization after estimate revisions and insider-sale signals.
What to watch
The article does not quantify trial progress or cash runway; traders may be over-weighting estimate revisions versus upcoming clinical milestones and balance-sheet updates.
Background
Erasca is a clinical-stage oncology company with an RAS/MAPK pipeline in early trials, so valuation is highly sensitive to modeled cash burn and financing conditions.
Ticker impact
Erasca shares fell nearly 4.9% after HC Wainwright cut multi-year per-share loss estimates and widened FY2027 loss forecast to $0.90.
Likely further pressure or choppy trading as the market reprices the company’s burn trajectory despite a separate bullish initiation.
The article ties the same-day drop directly to Wainwright’s revised loss forecasts and notes additional caution from a Form 144 insider sale filing.
Market effects
Clinical-stage biotechs may trade with higher sensitivity to cash-burn expectations and analyst loss-model revisions.
US broad indices down modestly, reinforcing a risk-off backdrop for unprofitable growth names.
US-focused risk sentiment and AI-chip export headlines are cited as contributing to broader market weakness, indirectly weighing biotech risk appetite.
Counterpoint
Leerink’s Outperform initiation with a $35 target could attract dip-buyers if investors view Wainwright’s cuts as conservative modeling rather than deteriorating fundamentals.
Key entities
- companyErasca
Clinical-stage oncology company whose shares fell nearly 4.9% on analyst estimate cuts and insider-selling signals.
- analyst_firmHC Wainwright
Lowered multi-year per-share loss estimates, widening FY2027 loss forecast from $0.58 to $0.90.
- analyst_firmLeerink Partners
Initiated coverage with an Outperform rating and a $35 price target.
- filingForm 144
Indicates a pending insider share sale disclosed on November 16, contributing to cautious positioning.

